Results 151 to 160 of about 90,273,184 (284)

Real‐world observational study evaluating metabolic and kidney outcomes in patients living with chronic kidney disease and type 2 diabetes mellitus with obesity prescribed tirzepatide

Diabetic Medicine, EarlyView.
Abstract Background Obesity and type 2 diabetes mellitus (T2DM) accelerate chronic kidney disease (CKD) progression. Tirzepatide, a dual glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonist, has demonstrated metabolic and potential renoprotective benefits in clinical trials.
Jack E. Carruthers, Xi Yan Ooi, Dawn Goodall, Jo Reed, Rachna Bedi, Adrian McGrath, Michelle Willicombe, Parizad Avari, Andrew H. Frankel   +8 more
wiley   +1 more source

Dietary approaches to stop hypertension (DASH): Results and implications [PDF]

American Journal of Hypertension, 1998
openaire   +1 more source

A 52‐Week Efficacy and Safety Study of Teneligliptin, as an Add‐On to Empagliflozin and Metformin in Patients With Type 2 Diabetes Mellitus: A Randomised, Double‐Blind, Placebo‐Controlled Phase 3 Trial (TERA305 Study)

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the long‐term efficacy and safety of teneligliptin add‐on in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and empagliflozin. Materials and Methods In this randomised, double‐blind, phase 3 trial, 214 patients received teneligliptin 20 mg (n = 107) or placebo (n = 107) once daily for 24 ...
Jun Sung Moon, Kyung Ah Han, Dong‐Lim Kim, Sang Yong Kim, Soo‐Kyung Kim, Bon Jeong Ku, Woo Je Lee, Tae Keun Oh, Ji A Seo, Sang‐Ah Chang, Moon‐Kyu Lee, Kyu Jeung Ahn, Chul Sik Kim, Tae Nyun Kim, Bong‐Soo Cha   +14 more
wiley   +1 more source

Dietary approaches to stop hypertension (DASH) in relation to hyper-triglyceridemic-waist (HTGW) phenotype in Iranian adults. [PDF]

Sci Rep
Pirmoradian M, Parvaresh A, Moradmand Z, Shahdadian F, Rouhani P, Soltani S, Saneei P.   +6 more
europepmc   +1 more source

Real‐World Cost and Utilisation Burden of Diagnosed Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes in the United States: A Retrospective Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This study quantified the real‐world healthcare costs and utilisation associated with diagnosed metabolic dysfunction‐associated steatotic liver disease (MASLD) among adults with Type 2 diabetes (T2D). Methods We conducted a retrospective cohort study using IQVIA PharMetrics Plus Closed Health Plan data from January 2016 to June 2025 ...
Tien Hoang Tran, Hyung‐Seok Kim, Rozalina G. McCoy, Zafar Zafari   +3 more
wiley   +1 more source

Weight Regain After Incretin Treatment: The Lean Mass Deficit Hypothesis and a Role for Testosterone Combination Therapy in Men

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), dual glucose‐dependent insulinotropic polypeptide (GIP)/GLP‐1RA and triple (GIP)/GLP‐1RA/glucagon agonists achieve placebo‐subtracted weight loss of 15% to 22%. Their long‐term value depends on how well the weight loss is maintained and on the composition of weight loss, not only
Michael Zitzmann, Zsolt Bosnyak, Richard Jones, Monica Caliber   +3 more
wiley   +1 more source

Association of Dietary Approaches to Stop Hypertension Diet With the Risk of Osteoporosis and Fracture: A Systematic Review and Meta-Analysis. [PDF]

Food Sci Nutr
Yang B, Hou J, Song X, Zheng S, Deng Q, Xiang R, Zhao X, Qu Y, Sha L, Zhu J, Lei B, Yu T, Han T, Zhou J, Liu T, Xia M, Zhong Y, Pu X, Jiang X.   +18 more
europepmc   +1 more source

Dapagliflozin Alters Plasma Metabolome in Patients With Type 1 Diabetes During Ketosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Use of sodium‐glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 1 diabetes (T1D) is limited by increased risk of ketoacidosis. We aimed to determine metabolic pathways affected by SGLT2i treatment in adults with T1D during ketosis induced by insulin withdrawal.
Rosa Yang, Kevin Cho, Max C. Petersen, Kai E. Jones, Gary J. Patti, Janet B. McGill, Samantha A. DiGruccio   +6 more
wiley   +1 more source

Qualitative study of barriers and facilitators to Dietary Approaches to Stop Hypertension (DASH) on the Caribbean island of Montserrat. [PDF]

BMJ Public Health
Berners-Lee B, Duberry N, Hazel-Blake D, Mallen C, Shepherd T, Tirion AS, Weston D, Greenaway-Duberry S, Pae R.   +8 more
europepmc   +1 more source

Glycaemic Management and Pregnancy Outcomes in HNF1A‐MODY

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Introduction Birthweight of HNF1A‐affected offspring is largely similar to the background population with rarely reported cases of large for gestational age (LGA) and neonatal hypoglycaemia (NH). Conventional clinical management of pre‐gestational diabetes appears to be sufficient in managing HNF1A‐affected women in pregnancy.
M. T. Crowley, P. McCluskey, N. Ng, B. Sanchez‐Lechuga, A. Fleming, M. Hatunic, B. Kinsley, S. Bacon, K. Colclough, M. Kennelly, M. M. Byrne   +10 more
wiley   +1 more source